Filtered By:
Condition: Heart Failure
Countries: China Health
This page shows you your search results in order of relevance. This is page number 6.
Order by Relevance | Date
Total 240 results found since Jan 2013.
Report on Cardiovascular Health and Diseases in China 2021: An Updated Summary
Biomed Environ Sci. 2022 Jul 20;35(7):573-603. doi: 10.3967/bes2022.079.ABSTRACTIn 2019, cardiovascular disease (CVD) accounted for 46.74% and 44.26% of all deaths in rural and urban areas, respectively. Two out of every five deaths were due to CVD. It is estimated that about 330 million patients suffer from CVD in China. The number of patients suffering from stroke, coronary heart disease, heart failure, pulmonary heart disease, atrial fibrillation, rheumatic heart disease, congenital heart disease, lower extremity artery disease and hypertension are 13.00 million, 11.39 million, 8.90 million, 5.00 million, 4.87 million, ...
Source: Biomedical and Environmental Sciences : BES - August 9, 2022 Category: Biomedical Science Authors: writing committee of the report on cardiovascular health and diseases in china Source Type: research
P ‐wave durations from automated electrocardiogram analysis to predict atrial fibrillation and mortality in heart failure
ConclusionsExtreme values of maximum P-wave durations ( ≤90 ms and ≥141 ms) were significant predictors of new-onset AF, cardiovascular mortality, and all-cause mortality.
Source: ESC Heart Failure - December 3, 2022 Category: Cardiology Authors: Jiandong Zhou,
Andrew Li,
Martin Tan,
Matthew Chung Yan Lam,
Lok Tin Hung,
Ronald Wing Hei Siu,
Sharen Lee,
Ishan Lakhani,
Jeffrey Shi Kai Chan,
Khalid Bin Waleed,
Tong Liu,
Kamalan Jeevaratnam,
Qingpeng Zhang,
Gary Tse Tags: Original Article Source Type: research
Effectiveness and safety of Shexiang Baoxin Pill (MUSKARDIA) in patients with stable coronary artery disease and concomitant diabetes mellitus: a subgroup analysis of a randomized clinical trial
CONCLUSION: As an add-on to standard therapy, MUSKARDIA shows a trend of reduced MACEs in patients with stable CAD and DM. Furthermore, MUSKARDIA may reduce the frequency of all-cause death, hospitalization, and coronary angioplasty in this population, especially in those with uncontrolled DM.TRIAL REGISTRATION: ChiCTR.org.cn, ChiCTR-TRC-12003513.PMID:36752805 | DOI:10.1097/CM9.0000000000002527
Source: Chinese Medical Journal - February 8, 2023 Category: General Medicine Authors: Jingmin Zhou Haiming Shi Fusui Ji Yang Wu Yulan Zhao Jun Qian Junbo Ge Source Type: research
